IHI — iShares U.S. Medical Devices ET

Is IHI overbought or oversold? Here is the current MarketMoodz read.

ETF

Oversold As of October 3, 2026

iShares U.S. Medical Devices ET (IHI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The ETF name last closed at $50.45. The rating moved from Neutral to Oversold on October 3, 2026.

See all oversold ETF stocks →

AI analysis

iShares U.S. Medical Devices ET (IHI) provides broad exposure to leading medical device companies that benefit from structural secular demand, steady cash flows, and ongoing innovation and M&A. Recent market conditions — cautious risk-off sentiment and geopolitical headlines — tend to favor defensive healthcare exposures and could support near-term ETF flows. Key catalysts include recovery in elective procedures, continued adoption of advanced device technologies, and potential M&A activity. Primary risks include regulatory/reimbursement headwinds, elective-procedure cyclicality, supply-chain disruption, and concentration in top constituents. Over the next month the ETF is positioned to modestly outperform if sector flows persist and macro volatility stabilizes, while downside remains if procedure volumes or regulatory actions deteriorate.

Key factors

  • iShares U.S. Medical Devices ET (IHI) offers diversified exposure to leading medical device manufacturers with historically steady revenue and cash generation
  • Structural demand drivers: aging populations, increasing procedure volumes, and long-term adoption of minimally invasive and robotic technologies
  • Defensive sector positioning that can attract flows in risk-off environments and during geopolitical uncertainty
  • Innovation and M&A activity in the medical devices space can drive cyclical upside for constituent equities
  • Relative valuation for some device names appears reasonable after recent market volatility, offering potential near-term upside
  • Lower Treasury yields following weaker payrolls can support equity multiples and M&A financing for the sector
  • ETF diversification reduces single-stock idiosyncratic risk compared with owning individual device names

Risks

  • Cyclical exposure to elective procedures — demand can decline in economic slowdowns or if patients postpone care
  • Regulatory and reimbursement risk across major markets (FDA approval timelines, pricing pressure, payer negotiations)
  • Supply-chain and manufacturing disruptions, including shipping risks tied to geopolitical developments
  • Concentration risk in top holdings — poor performance at a few large constituents can materially impact the ETF
  • Currency and international revenue exposure could weigh on results if the dollar moves unfavorably
  • Elevated market volatility from retail/derivative flows and rapidly shifting macro prints can cause short-term dislocations
  • Potential longer-term pressure if interest rates re-accelerate, increasing discount rates and raising M&A funding costs

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for IHI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.